Erba Diagnostics Inc (ERB) 2.45 $ERB
ERBA Diagnostics, Inc. to Exhibit at AACC 2014 in Chicago, USA
GlobeNewswire - Mon Jul 28, 7:06AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the world's largest show for Clinical Chemistry - American Association for Clinical Chemistry (AACC) in Chicago, Illinois, U.S.A., from July 28-31, 2014.
ERBA Diagnostics names William Creech as VP of Sales and Marketing
M2 - Mon Jun 23, 6:12AM CDT
In vitro diagnostics company ERBA Diagnostics (NYSE MKT:ERB) disclosed on Friday the addition of William Creech as vice president of its Sales and Marketing.
ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing
GlobeNewswire - Fri Jun 20, 8:58AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, has appointed William Creech as Vice President Sales and Marketing.
ERBA Diagnostics, Inc. Appoints Mohan Gopalkrishnan as Chief Executive Officer and Prakash Patel as Controller
Business Wire - Tue May 27, 3:30PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Chief Executive Officer and Prakash Patel as Controller of ERBA Diagnostics, both effective as of June 1, 2014. Mr. Mohan is currently Vice President - Operations of ERBA Diagnostics. Mr. Patel is currently the Assistant Controller, Principal Financial Officer and Principal Accounting Officer of ERBA Diagnostics. Each of Mr. Mohan and Mr. Patel will continue to be based in ERBA Diagnostics' Miami Lakes headquarters.
ERBA Diagnostics, Inc. Receives 510(K) Clearance for the XL200 Clinical Chemistry Analyzer
Business Wire - Wed May 21, 7:01AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) on the 510(k) premarket submission that ERBA Diagnostics had filed for its new clinical chemistry analyzer - the XL 200.
ERBA Diagnostics, Inc. Announces Delay in Filing Annual Report on Form 10-K
Business Wire - Mon Mar 31, 7:25AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, announced that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission (the "SEC"
.
ERBA Diagnostics Inc. to Exhibit at Medlab Asia Pacific Singapore Feb 18-20, 2014
Business Wire - Wed Feb 12, 7:00AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the prestigious Medical show in Asia, Medlab Asia Pacific, Singapore Feb. 18-20 2014.
3 Stocks Under $10 Moving Higher
at The Street - Wed Feb 12, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ERBA Diagnostics, Inc. to Attend JP Morgan 32nd Annual Healthcare Conference
Business Wire - Mon Jan 13, 8:29AM CST
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be attending the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California from January 13-16, 2014. ERBA will be sharing a company presentation with some of the investors present at the conference and has filed an 8K with the presentation as an exhibit.
ERBA Diagnostics, Inc. Exhibits at Arab Health 2014, Dubai, U.A.E.
Business Wire - Wed Jan 08, 6:59AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the largest Medical show in the Middle East and Africa, Arab Health in Dubai, U.A.E. Jan 27-30, 2014. ERBA, along with some of the world leaders in IVD, has been nominated as the GOLD Sponsor of the show.
ERBA Diagnostics, Inc. Reports Second Quarter 2013 Financial Results
Business Wire - Mon Aug 19, 3:15PM CDT
--Posts positive net income for the second quarter
ERBA Diagnostics Resolves Prior Non-Compliance by Filing 10-Q
Business Wire - Mon Aug 19, 3:05PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, announced today that the Company has received a letter from the NYSE MKT LLC (the "Exchange" stating that the Company has resolved its prior non-compliance with the continued listing standards contained in the Exchange's Company Guide relating to Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, because the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on August 9, 2013.
ERBA Diagnostics, Inc. Reports First Quarter 2013 Financial Results
Business Wire - Tue Aug 13, 7:00AM CDT
--- - Made a profit at operating income level - -
ERBA Diagnostics Inc to dsiplay products at largest clinical lab exposition in the world, AACC's Clinical Lab Expo
M2 - Mon Jul 29, 6:02AM CDT
In vitro diagnostics company ERBA Diagnostics Inc (NYSE MKT:ERB) said on Friday that it will be displaying its full range of products at the largest clinical lab exposition in the world, AACC's Clinical Lab Expo in Houston.
ERBA DIAGNOSTICS Exhibits at AACC Houston, "The Largest Clinical Lab Exposition in the World"
Business Wire - Sun Jul 28, 11:17AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be exhibiting the full range of products from ERBA Diagnostics group including not only the Autoimmune and Infectious Elisa product lines, but also the new product lines from its Drew Scientific and Jas Diagnostics subsidiaries of hematology and Hb1AC equipment and reagents. ERBA Diagnostics will also be displaying its full line of biochemistry, clinical chemistry and urine analysis products of the parent company, ERBA Diagnostics Mannheim GmbH and group companies in India, Czech Republic, France and Italy.
ERBA Diagnostics' 10-Q Compliance Plan Accepted by NYSE MKT
Business Wire - Tue Jun 25, 3:15PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB) (the "Company", a fully integrated in vitro diagnostics company, announced today that the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has accepted the Company's plan of compliance (the "10-Q Plan" for continued listing relating to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
ERBA Diagnostics Exhibits at EuroMedlab Conference in Milan, Italy
Business Wire - Thu May 23, 8:28AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce its participation at the Euromedlab conference in Milan, Italy, May 19th thru May 23rd. EuroMedlab is the European Congress of Clinical Chemistry and Laboratory Medicine.
ERBA Diagnostics, Inc. Announces Notice of Noncompliance with NYSE MKT Continued Listing Standards
Business Wire - Wed May 22, 3:30PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company", a fully integrated in vitro diagnostics company, announced today that, on May 17, 2013, the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission (the "SEC". The letter also states that the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from
ERBA Diagnostics Inc elects Mohan Gopalkrishnan as V of, Operations
M2 - Fri Feb 08, 10:10AM CST
In vitro diagnostics company ERBA Diagnostics Inc (NYSE MKT:ERB) revealed on Thursday the addition of Mohan Gopalkrishnan as vice president of its Operations.
ERBA Diagnostics, Inc. to Exhibit at AACC 2014 in Chicago, USA
GlobeNewswire - Mon Jul 28, 7:06AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the world's largest show for Clinical Chemistry - American Association for Clinical Chemistry (AACC) in Chicago, Illinois, U.S.A., from July 28-31, 2014.
ERBA Diagnostics names William Creech as VP of Sales and Marketing
M2 - Mon Jun 23, 6:12AM CDT
In vitro diagnostics company ERBA Diagnostics (NYSE MKT:ERB) disclosed on Friday the addition of William Creech as vice president of its Sales and Marketing.
ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing
GlobeNewswire - Fri Jun 20, 8:58AM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, has appointed William Creech as Vice President Sales and Marketing.
ERBA Diagnostics, Inc. Appoints Mohan Gopalkrishnan as Chief Executive Officer and Prakash Patel as Controller
Business Wire - Tue May 27, 3:30PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Chief Executive Officer and Prakash Patel as Controller of ERBA Diagnostics, both effective as of June 1, 2014. Mr. Mohan is currently Vice President - Operations of ERBA Diagnostics. Mr. Patel is currently the Assistant Controller, Principal Financial Officer and Principal Accounting Officer of ERBA Diagnostics. Each of Mr. Mohan and Mr. Patel will continue to be based in ERBA Diagnostics' Miami Lakes headquarters.
ERBA Diagnostics, Inc. Receives 510(K) Clearance for the XL200 Clinical Chemistry Analyzer
Business Wire - Wed May 21, 7:01AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) on the 510(k) premarket submission that ERBA Diagnostics had filed for its new clinical chemistry analyzer - the XL 200.
ERBA Diagnostics, Inc. Announces Delay in Filing Annual Report on Form 10-K
Business Wire - Mon Mar 31, 7:25AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, announced that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission (the "SEC"
. ERBA Diagnostics Inc. to Exhibit at Medlab Asia Pacific Singapore Feb 18-20, 2014
Business Wire - Wed Feb 12, 7:00AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the prestigious Medical show in Asia, Medlab Asia Pacific, Singapore Feb. 18-20 2014.
3 Stocks Under $10 Moving Higher
at The Street - Wed Feb 12, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ERBA Diagnostics, Inc. to Attend JP Morgan 32nd Annual Healthcare Conference
Business Wire - Mon Jan 13, 8:29AM CST
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be attending the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California from January 13-16, 2014. ERBA will be sharing a company presentation with some of the investors present at the conference and has filed an 8K with the presentation as an exhibit.
ERBA Diagnostics, Inc. Exhibits at Arab Health 2014, Dubai, U.A.E.
Business Wire - Wed Jan 08, 6:59AM CST
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the largest Medical show in the Middle East and Africa, Arab Health in Dubai, U.A.E. Jan 27-30, 2014. ERBA, along with some of the world leaders in IVD, has been nominated as the GOLD Sponsor of the show.
ERBA Diagnostics, Inc. Reports Second Quarter 2013 Financial Results
Business Wire - Mon Aug 19, 3:15PM CDT
--Posts positive net income for the second quarter
ERBA Diagnostics Resolves Prior Non-Compliance by Filing 10-Q
Business Wire - Mon Aug 19, 3:05PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, announced today that the Company has received a letter from the NYSE MKT LLC (the "Exchange"
stating that the Company has resolved its prior non-compliance with the continued listing standards contained in the Exchange's Company Guide relating to Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, because the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on August 9, 2013. ERBA Diagnostics, Inc. Reports First Quarter 2013 Financial Results
Business Wire - Tue Aug 13, 7:00AM CDT
--- - Made a profit at operating income level - -
ERBA Diagnostics Inc to dsiplay products at largest clinical lab exposition in the world, AACC's Clinical Lab Expo
M2 - Mon Jul 29, 6:02AM CDT
In vitro diagnostics company ERBA Diagnostics Inc (NYSE MKT:ERB) said on Friday that it will be displaying its full range of products at the largest clinical lab exposition in the world, AACC's Clinical Lab Expo in Houston.
ERBA DIAGNOSTICS Exhibits at AACC Houston, "The Largest Clinical Lab Exposition in the World"
Business Wire - Sun Jul 28, 11:17AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be exhibiting the full range of products from ERBA Diagnostics group including not only the Autoimmune and Infectious Elisa product lines, but also the new product lines from its Drew Scientific and Jas Diagnostics subsidiaries of hematology and Hb1AC equipment and reagents. ERBA Diagnostics will also be displaying its full line of biochemistry, clinical chemistry and urine analysis products of the parent company, ERBA Diagnostics Mannheim GmbH and group companies in India, Czech Republic, France and Italy.
ERBA Diagnostics' 10-Q Compliance Plan Accepted by NYSE MKT
Business Wire - Tue Jun 25, 3:15PM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has accepted the Company's plan of compliance (the "10-Q Plan" for continued listing relating to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. ERBA Diagnostics Exhibits at EuroMedlab Conference in Milan, Italy
Business Wire - Thu May 23, 8:28AM CDT
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce its participation at the Euromedlab conference in Milan, Italy, May 19th thru May 23rd. EuroMedlab is the European Congress of Clinical Chemistry and Laboratory Medicine.
ERBA Diagnostics, Inc. Announces Notice of Noncompliance with NYSE MKT Continued Listing Standards
Business Wire - Wed May 22, 3:30PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that, on May 17, 2013, the Company received a letter from NYSE MKT LLC (the "Exchange" stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission (the "SEC". The letter also states that the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from ERBA Diagnostics Inc elects Mohan Gopalkrishnan as V of, Operations
M2 - Fri Feb 08, 10:10AM CST
In vitro diagnostics company ERBA Diagnostics Inc (NYSE MKT:ERB) revealed on Thursday the addition of Mohan Gopalkrishnan as vice president of its Operations.
